How tech, regulation and workforce economics are redefining Biopharma in Western Europe

Western Europe’s biopharma and life sciences sector (BPLS) is at a structural inflection point. Innovation remains essential but is no longer the primary differentiator. Competitive advantage is increasingly defined by the ability to scale innovation under multiple constraints, including regulatory, operational and, most critically, workforce.  

However, based on WTW’s latest compensation survey data, a clear pattern is emerging: Life science leaders are differentiating not through better science, but through improved discipline around execution of core business strategies, sharper workforce strategies and the more precise use of rewards.

AI is no longer a capability. It's the operating system.

AI has decisively moved into core infrastructure across the industry’s value chain, from discovery to clinical operations and commercial analytics. Simultaneously, AI also is reshaping the workforce in unequal ways. AI is:

• Accelerating demand for hybrid digital-scientific talent
• Compressing or redesigning traditional R&D roles
• Widening pay dispersion within functions

Going beyond creating new roles, AI is systemically eroding the value of other roles, increasing internal inequality as a structural feature, not a flaw. Additionally, digital and AI roles in life sciences markets are seeing even two times’ higher salary increases than non-digital populations, according to WTW’s 2026 Salary Budget Planning Report — Global (July).

Given this, AI can’t be treated as an add-on. It is reshaping how work, decisions and accountability fit together. That shift calls for a fundamental redesign of critical roles, career models and pay structures — not incremental hiring.

Ultimately, organizations that fail to structurally integrate AI will create fragmented, inefficient and unsustainable talent models.

Advanced therapies: The bottleneck has shifted

Cell and gene therapies have crossed the scientific threshold, with some having proven they work and others officially being approved. The constraint is no longer innovation, it’s execution. Today’s critical pressure points have shifted from:

• Scientific feasibility to manufacturing scalability
• Clinical approval to regulatory navigation
• Early-stage logistics to supply chain resilience

We see pay premiums for advanced manufacturing and quality roles outpacing broader market increases, reflecting a shortage of specialized talent rather than cyclical demand. This reflects that pipeline strength is no longer enough. Organizations must overinvest deliberately and early in having the right people, processes and systems to produce and deliver therapies at scale — or risk being unable to convert innovation into revenue.

Sustainability is becoming a talent filter

With sustainability moving from a narrative to being an operating requirement, we see it directly influencing capital allocation, supply chain design and employer attractiveness.

Early-career employees are increasingly willing to trade compensation for employers that are aligned with sustainability values, particularly in science and engineering roles, creating a constraint that moves beyond operations to talent access.  

Failing to operationalize sustainability commitments will have direct consequences: It will distort capital allocation decisions (as ESG-linked investments and funding become harder to access), weaken supply chain resilience (through non-compliance or misaligned partners), and reduce employer attractiveness, ultimately limiting hiring capability and increasing cost.

M&A: The value is in people, not assets

M&A activity in the BPLS industry has become more selective, shifting toward acquiring capabilities, not scalability.  

This shows that industry organizations are focused on specialist talent and intellectual capital — making integration risk a retention risk. In capability-led acquisitions, losing even a small number of critical experts can materially reduce deal value.

This risk requires organizations to look beyond outdated, traditional integration models. Retention must be engineered through targeted, front-loaded incentives and differentiated career propositions within the first six to 12 months of post-merger integration — when talent flight risk is highest. Delay will destroy value.

Pay transparency will break legacy reward systems

The EU Pay Transparency Directive isn’t just a compliance requirement, it’s a structural stress test that exposes inconsistent job architecture, legacy pay decisions and misaligned progression frameworks.

We see early pay transparency adopters identifying material pay inconsistences across 20% to 30% of roles, particularly in legacy and support functions. Essentially, many organizations are not “slightly misaligned,” they’re structurally mispriced.

The lesson here is that compliance-led approaches will fail. Organizations must conduct an end-to-end redesign of job architecture, pay governance and progression logic.

Stability has returned, making precision more important than ever

The macroeconomic environment has stabilized, but factors like inflation normalization, moderated salary growth and persistent country-level divergence are keeping complexity from decreasing.  

Across Western Europe, we see that organizations are adapting to stable salary budgets by rewarding critical roles up to two times the average increase, reflecting targeted allocation. This tells us that, going forward, broad-based pay strategies will become more inefficient than they already are.

Winning BPLS organizations will manage rewards with granular precision by skill, role and geography. Anything less will result in misallocated costs.

Talent scarcity is a system-design problem

Talent scarcity persists, but the root cause for that scarcity has changed. Today, it’s being driven by factors like skill mismatches, geographic constraints and structural misalignment between roles and capabilities.  

Additionally, unresolved hybrid work is creating friction between leadership expectations (i.e., control, visibility) and employee expectations (i.e., flexibility, autonomy). Talent scarcity has become less about the lack of talent and more about how work is structured and managed in a hybrid environment.

While it may seem logical to look for more talent, organizations should start by looking at their existing workforce. Frequently, we see that employers aren’t short on talent; rather, their framework is poorly configured and does not support the use of existing talent.

Instead of adding headcount, organizations need to consider systematic reskilling, workforce reconfiguration and internal mobility at scale.

Compensation is becoming more unequal, but more strategic

Compensation is becoming a precision instrument of strategy in the BPLS industry. We are increasingly seeing widening pay dispersion, sharper differentiation by skill and increased scrutiny under transparency.

Organizations that successfully differentiate pay are those that can clearly articulate and defend the logic behind it, both internally and externally. You can’t avoid pay inequality, but you must be able to design and explain it intentionally. Failure here will lead to disengagement, reputational risk and regulatory exposure.

What leaders must do

Incremental change is no longer sufficient for BPLS organizations. Your advantage requires decisive action (Table 1). 

The new competitive divide

The biopharma and life sciences industry is no longer divided between innovators and followers. It’s now divided between organizations that can execute end-to-end and at scale vs. those that cannot. The next winners will be those organizations that:

• Treat workforce strategy as core business infrastructure
• Use rewards as a precision lever not a cost tool
• Act early, structurally and decisively

The next phase for biopharma firms won’t fail because of a lack of innovation. Failure will come from the inability to operationalize innovation into approved, accessible and scalable therapies fast enough, fairly enough or at scale.